Sensei Biotherapeutics, Inc. (SNSE)
| Market Cap | 215.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 30.59M |
| EPS (ttm) | -2.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,224 |
| Open | 6.95 |
| Previous Close | 6.97 |
| Day's Range | 6.71 - 7.10 |
| 52-Week Range | 6.68 - 26.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 3, 2021 |
About SNSE
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which furt...
Financial Performance
Financial StatementsNews
Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Proprietary Anti-VISTA Antibody, at the 36th An...
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
Sensei Biotherapeutics, Inc. (SNSE) Upgraded to Buy: Here's Why
Sensei Biotherapeutics, Inc. (SNSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sensei Biotherapeutics Reports Second Quarter 2021 Results and Highlights Recent In Vivo Data from SNS-VISTA Program
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model –
Sensei Biotherapeutics Appoints Kristian Humer to its Board of Directors
BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today...
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
You might not have heard of them, but one went up big while the other served up a massive disappointment.
Sensei Biotherapeutics Announces Prioritization of Next-Generation Multi-Antigenic ImmunoPhage Platform, Monoclonal A...
- Company to focus on development of next-generation phage product candidates from ImmunoPhage platform and monoclonal antibody and nanobody programs -
5 Stocks With High Guru and Insider Buys in the Past 3 Months
According to the Double Buys page, a Premium feature of GuruFocus, five stocks that had multiple guru and insider buys during the second quarter are PennyMac Financial Services inc. ( PFSI , Financial),...
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patient...
– Data continue to show that SNS-301 in combination with pembrolizumab is well tolerated –
Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
- ImmunoPhage™ platform programs and the VISTA program continue to advance -
Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D.
BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generati...
Sensei Biotherapeutics Appoints Jessie M. English, Ph.D.
Entrepreneurial leader brings expertise growing biotech platform companies Entrepreneurial leader brings expertise growing biotech platform companies
Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update
-Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds –
Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference
BOSTON and ROCKVILLE, Md., March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutic...
Sensei Biotherapeutics Announces Closing of Initial Public Offering
BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics...
Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics...
Sensei Biotherapeutics Announces Launch of Initial Public Offering
BOSTON & ROCKVILLE, Md.--Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced...
Sensei Biotherapeutics IPO Registration Document (S-1)
Sensei Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Cancer biotech Sensei Biotherapeutics files for a $100 million IPO
Sensei Biotherapeutics, a Phase 2 biotech developing bacteriophage-based therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Uma Thurman invests in cancer immunotherapy company
Sensei Biotherapeutics, a clinical-stage cancer immunotherapy company that opened a Boston research and development hub last year, has attracted high-profile investors for its $30 million Series B round.